Would not sell it here. A quarter of the market cap is in cash. Lots of opportunity to do new deals. Lots of growth opportunities to come. The next catalyst could be a share buyback or large special dividend. It’s a keeper.
(A Top Pick June 18/12. Up 15.18%.) Still likes. Has a massive cash position but in the last couple of weeks have announced a couple of loan deals where they are lending money to other pharmaceutical companies at a high level of interest. Have also announced some new blockbuster drugs that they are going to market in Canada and the US.
(A Top Pick May 7/12. Up 14.55%.) Very high ROC. Sitting on a lot of cash and keeps wondering when they are going to do something major with it. It is starting to make their ROE turn over so he, from a portfolio point of view, will have to make a decision.
Very consistent earnings. Having their annual meeting next week and he would hope that they will declare a big dividend. Generates about $80 million a year and have about $250 million of cash on their books and no debt.
(A Top Pick Jan 13/12. Up 1.73%.) Have a massive amount of cash. Last year’s under performer but looks like it is a star in his portfolio this year.
(A Top Pick Dec 12/11. Up 2.79%.) A bit of a weak quarter because of problems in South Africa. Everything is good. The problems in South Africa are just a current quarter type of thing and is part of the consolidation process. Biggest issue going forward is that they have an $850 million market cap with $250 million of cash. In terms of enterprise value to EBITDA it is trading at 6 times. Throws off a ton of excess cash flow.
They don't have a huge exposure into any one area. We don't get a huge amount of detail on their overseas operations. His bigger issue is the cash keeps building up in this company and is starting to undermine the return on equity.
Paladin Labs Inc is a OTC stock, trading under the symbol PLB-T on the (). It is usually referred to as or PLB-T
In the last year, there was no coverage of Paladin Labs Inc published on Stockchase.
Paladin Labs Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Paladin Labs Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Paladin Labs Inc In the last year. It is a trending stock that is worth watching.
On , Paladin Labs Inc (PLB-T) stock closed at a price of $.
His 3rd largest position. A good buy at $63 mark. Thinks they are over capitalized and could institute a dividend.